GlassScriptPhysician profile
Michael Jeffrey Reep
NPI 1316407570
$6,355.19
in general payments reported to CMS, 2019-2025
20 companies · $790 in 2025
The $790 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $353 · 2022: $811 · 2023: $2,509 · 2024: $1,892 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,991 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,991.10 |
| Education | $199.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,916.65 | 2021-2025 | Otezla, Tavneos, Krystexxa |
| Abbvie INC. | $1,501.03 | 2022-2025 | |
| Ucb, INC. | $406.96 | 2022-2023 | Cimzia |
| Novartis Pharmaceuticals Corporation | $345.68 | 2023-2024 | |
| Glaxosmithkline, LLC. | $336.27 | 2021-2025 | Benlysta |
| Janssen Scientific Affairs, LLC | $318.82 | 2023-2024 | Tremfya |
| Aurinia Pharma U.S., INC. | $287.90 | 2023-2024 | Lupkynis |
| Sanofi-Aventis U.S. LLC | $263.58 | 2022-2024 | |
| Mallinckrodt Hospital Products INC. | $224.98 | 2022 | |
| Genzyme Corporation | $191.15 | 2023 | |
| Pfizer INC. | $142.58 | 2022-2024 | |
| Janssen Biotech, INC. | $85.26 | 2023-2024 | Tremfya, Simponi Aria |
| Fresenius Kabi USA, LLC | $64.09 | 2023-2024 | Idacio |
| Alexion Pharmaceuticals, INC. | $62.29 | 2022-2024 | Strensiq |
| Octapharma USA, INC. | $56.10 | 2023-2024 | Octagam Immune Globulin (Human) |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $45.12 | 2022-2023 | |
| Horizon Therapeutics Plc | $41.63 | 2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $34.89 | 2024-2025 | Saphnelo |
| Lilly USA, LLC | $16.35 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $13.86 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Reep listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.